Manel Merabet
Chief Development Officer Skymab Therapeutics
Seminars
Thursday 21st August 2025
Advancing Site-Specific ADC Conjugation: Skymab’s Next-Generation Platform & First Preclinical Insights
1:30 pm
- Innovations in site-specific ADC conjugation – overcoming the limitations of traditional maleimide chemistry
- Skymab’s novel platform – enhancing stability, DAR control, and therapeutic index through optimized linker strategies
- Preclinical results and future directions – first insights into Skymab’s lead ADC candidate and its potential clinical impact
